Pacific Biosciences of California, Inc.

https://www.pacb.com

Pacific Biosciences of California, Inc., commonly known as PacBio, is an American biotechnology company established in 2004. Headquartered in Menlo Park, California, its core business involves developing and manufacturing advanced systems for gene sequencing and real-time biological observation. The company's mission is to enable the promise of genomics to better human health by providing comprehensive genomic insights.

PacBio's key offerings include sequencing systems such as the Revio, Vega, Sequel Systems (Sequel II and IIe), and Onso, which are powered by its proprietary Single-Molecule Real-Time (SMRT) sequencing technology. This technology delivers highly accurate long reads, known as HiFi sequencing, and also incorporates Sequencing by Binding (SBB) technology for short reads. The company provides consumables, software like SMRT Link, and comprehensive support services. PacBio's solutions cater to diverse market segments, including human health (e.g., rare diseases, oncology), plant and animal sciences, infectious disease research, and biopharmaceutical development.

Under the leadership of President & CEO Christian Henry and Chairman of the Board John F. Milligan, PacBio continues to advance its market position. Recent strategic moves include the sale of short-read sequencing assets in January 2026 to sharpen its focus on long-read sequencing. The company has also engaged in notable partnerships, such as collaborations with Lucid Genomics for tertiary analysis, Covaris for workflows enabling HiFi sequencing of FFPE tumor samples, and Basecamp Research for the Trillion Gene Atlas Initiative. Additionally, PacBio joined the iHope initiative in early 2026 to expand access to genetic testing for rare diseases and appointed Chris Gibson to its Board of Directors in March 2026, bringing expertise in AI-driven biology. The company reported a 14% year-over-year revenue growth in Q4 2025, reflecting its ongoing efforts to improve commercial execution and expand its product offerings.

Latest updates

PacBio Integrates Bioinformatics Workflow with Lucid Genomics

Event summary

  • PacBio has named Lucid Genomics as a 'PacBio Compatible' partner.
  • The collaboration focuses on tertiary analysis of long-read sequencing data, specifically using Lucid Genomics’ bioinformatics platform.
  • Lucid Genomics’ platform supports tasks like variant annotation, methylation analysis, and visualization.
  • The partnership aims to streamline the process of translating sequencing data into actionable insights for labs of all sizes.

The big picture

The collaboration between PacBio and Lucid Genomics underscores the growing importance of bioinformatics in unlocking the full potential of long-read sequencing. While long-read sequencing technologies like PacBio’s HiFi sequencing offer significant advantages in resolving complex genomic regions, the ability to efficiently and accurately analyze the resulting data is crucial for driving adoption in clinical and research settings. This partnership aims to address a critical bottleneck in the sequencing workflow, potentially accelerating the translation of genomic insights into clinical applications.

What we're watching

Market Adoption
The success of this partnership hinges on Lucid Genomics’ ability to gain traction within PacBio’s existing customer base and attract new labs seeking streamlined tertiary analysis workflows.
Competitive Landscape
The long-read sequencing market is increasingly crowded; this collaboration will be tested against other bioinformatics solutions vying for integration with PacBio's platform.
Workflow Validation
The long-term value of this integration will depend on the continued validation and optimization of Lucid Genomics’ workflows with PacBio’s HiFi sequencing data, ensuring accuracy and reliability.

PacBio, Covaris Workflow Boosts HiFi Sequencing of Archived Tumor Samples

Event summary

  • PacBio and Covaris have jointly developed a workflow for HiFi long-read sequencing of formalin-fixed, paraffin-embedded (FFPE) tumor samples.
  • The workflow integrates Covaris’ truXTRAC FFPE extraction technology with PacBio’s Kinnex library preparation and Revio sequencing system.
  • Early studies generated over 100 million HiFi reads per sample, detecting over 5 million small variants and over 11,000 structural variants.
  • The workflow achieves approximately 60% direct phasing of variants, a significant improvement over short-read sequencing methods.
  • PacBio’s SPRQ-Nx technology is enabling a lower cost per genome, making this workflow more accessible for clinical researchers.

The big picture

The ability to reliably sequence FFPE samples, a vast and historically underutilized resource, represents a significant advancement in genomic research and clinical diagnostics. This joint workflow addresses a key bottleneck in oncology research, potentially unlocking insights from archived tumor samples and accelerating the development of targeted therapies. The increased variant detection and phasing capabilities could also improve the accuracy of cancer risk assessments and treatment decisions.

What we're watching

Clinical Adoption
The extent to which clinical researchers adopt this workflow will depend on demonstrated utility and cost-effectiveness compared to existing short-read sequencing approaches, particularly in routine diagnostics.
Regulatory Hurdles
As FFPE sequencing becomes more prevalent in clinical settings, regulatory scrutiny of the workflow and its data interpretation will likely increase, potentially impacting commercialization timelines.
Competitive Response
Other sequencing technology providers will likely respond to this advancement, potentially introducing competing solutions or partnerships that could erode PacBio and Covaris’ market share.

PacBio Secures Landmark Sequencing Deal to Fuel AI-Driven Drug Design

Event summary

  • PacBio has been selected by Basecamp Research to power the Trillion Gene Atlas, a project aiming to generate and model biological data at a trillion-gene scale.
  • The collaboration will involve sequencing approximately 100,000 samples from over 31 countries.
  • Basecamp Research's EDEN model utilizes metagenomic data, and PacBio’s HiFi sequencing is crucial for preserving genomic context needed for AI training.
  • PacBio will leverage its Revio® system and SPRQ-Nx chemistry to improve sequencing efficiency and cost-effectiveness.

The big picture

The partnership highlights the growing convergence of AI and genomics, where high-quality, large-scale genomic data is becoming a critical input for advanced AI models in drug discovery. Basecamp’s focus on metagenomics underscores the shift towards leveraging environmental data to uncover novel therapeutic targets. PacBio’s involvement positions it as a key infrastructure provider in this emerging ecosystem, but also exposes it to the risks associated with a concentrated customer base and the performance of third-party AI models.

What we're watching

Execution Risk
Sequencing 100,000 samples across diverse geographies presents significant logistical and quality control challenges that could impact the project timeline and data integrity.
Model Dependency
Basecamp’s reliance on PacBio’s HiFi sequencing creates a vendor lock-in risk, and the success of their EDEN model is directly tied to the quality and completeness of the sequenced data.
Competitive Landscape
The Trillion Gene Atlas initiative will likely accelerate competition in the long-read sequencing market, potentially pressuring PacBio’s pricing and market share.

PacBio Adds Recursion Founder to Board, Signals AI Integration Push

Event summary

  • PacBio appointed Christopher Gibson, co-founder and Chairman of Recursion, to its Board of Directors, effective March 5, 2026.
  • Gibson led Recursion's development of an AI-driven drug discovery platform, integrating large-scale biological data generation with machine learning.
  • Recursion is a clinical-stage biotechnology company listed on NASDAQ (RXRX).
  • PacBio is a leading provider of high-quality, long-read sequencing technologies, also listed on NASDAQ (PACB).

The big picture

PacBio’s appointment of Christopher Gibson signals a strategic pivot towards leveraging artificial intelligence and advanced analytics to extract greater value from its long-read sequencing data. This move reflects a broader trend in the life sciences industry, where computational biology and machine learning are increasingly essential for accelerating drug discovery and diagnostics. Recursion’s success in industrializing drug discovery through AI positions Gibson as a valuable asset for PacBio as it seeks to expand its market reach and enhance its competitive position.

What we're watching

Integration Risk
The success of PacBio’s strategy hinges on Gibson’s ability to effectively translate Recursion’s AI-driven approach to its sequencing data, which may require significant internal restructuring and process changes.
Data Scale
PacBio must demonstrate it can generate and manage the massive datasets required to train and deploy machine learning models, as Recursion has done, to validate the strategic value of Gibson’s expertise.
Competitive Landscape
The convergence of long-read sequencing and AI is attracting increased competition; PacBio’s ability to differentiate its offerings and maintain a technological edge will be crucial for sustained growth.

PacBio, DNAstack Consortium Expands Federated Genomics Data Sharing

Event summary

  • PacBio and DNAstack launched the HiFi Solves Global Consortium in 2023 to facilitate federated genomic data sharing.
  • The consortium now comprises nearly 30 institutions across 15 countries, with commitments to connect over 10,000 HiFi whole genome sequences.
  • A major study published in November 2025 demonstrated 100% variant detection using federated HiFi sequencing.
  • The platform enables secure data querying across institutions while maintaining compliance with regional data privacy regulations.

The big picture

The HiFi Solves Global Consortium represents a significant shift towards federated data models in genomics research, addressing the challenge of accessing large, diverse datasets while respecting data sovereignty. This approach is increasingly important as genomic data volumes grow exponentially and regulatory scrutiny intensifies. By enabling secure, collaborative analysis, PacBio and DNAstack are positioning themselves at the forefront of a trend that could fundamentally change how rare disease research is conducted.

What we're watching

Regulatory Headwinds
The consortium's ability to maintain compliance with evolving international data privacy regulations will be crucial for its long-term viability, particularly as it expands into new regions.
Adoption Rate
The pace at which additional institutions join the consortium and contribute data will determine the overall value and impact of the federated dataset.
Competitive Landscape
How other sequencing technology providers and data sharing platforms respond to this model will shape the future of collaborative genomic research.

PacBio to Detail Strategy at TD Cowen Healthcare Conference

Event summary

  • PacBio management will participate in a fireside chat at the TD Cowen Healthcare Conference.
  • The event is scheduled for March 2, 2026, in Boston, MA.
  • A live webcast will be available on PacBio's investor relations page.
  • The webcast replay will be accessible for at least 30 days following the event.

The big picture

PacBio's participation in the TD Cowen conference signals an effort to engage with investors and analysts amidst ongoing scrutiny of the genomics sector. The fireside chat provides a platform to address concerns about growth, competition, and the company's long-term strategic direction. The company's HiFi sequencing technology remains a key differentiator, but its success hinges on expanding applications and navigating the complexities of clinical adoption.

What we're watching

Growth Trajectory
How PacBio’s expansion into emerging applications like infectious disease and oncology will impact revenue growth, given the competitive landscape and regulatory hurdles in those areas.
Competitive Pressure
Whether PacBio can sustain its technological advantage in long-read sequencing as competitors continue to innovate and potentially lower costs.
Commercial Execution
The pace at which PacBio can translate its technological advancements into broader adoption and increased market share, particularly within clinical research settings.

PacBio Revenue Growth Masks Rising Losses Amid SPRQ-Nx Launch

Event summary

  • PacBio reported Q4 2025 revenue of $44.6 million, a 14% year-over-year increase, and full-year revenue of $160 million, up 4% year-over-year.
  • Consumables revenue reached a record $21.6 million in Q4 2025, while instrument revenue declined year-over-year to $17.3 million.
  • The company reported a GAAP net loss of $40.4 million in Q4 2025 and a full-year GAAP net loss of $546.4 million, driven by increased operating expenses.
  • PacBio completed the sale of its short-read sequencing assets, generating net cash proceeds of approximately $48.1 million.
  • The company anticipates the launch of SPRQ-Nx, a new sequencing platform aimed at lowering sequencing costs, in 2026.

The big picture

PacBio's revenue growth is encouraging, but the substantial net losses highlight ongoing challenges in achieving profitability. The sale of short-read assets was intended to sharpen the company’s focus on long-read sequencing, but the continued high operating expenses suggest that scaling the business and achieving margin expansion will require significant execution. The upcoming SPRQ-Nx platform represents a critical inflection point, as its success will dictate PacBio’s ability to compete effectively and drive sustainable growth in the rapidly evolving genomics market.

What we're watching

Cost Structure
Whether PacBio can achieve the promised cost reductions with SPRQ-Nx and translate that into improved profitability remains a key risk, given the substantial net losses reported.
Clinical Adoption
The pace at which clinical adoption of PacBio’s long-read sequencing technology accelerates will determine the sustainability of consumables revenue growth and overall market penetration.
Competition
How PacBio’s competitors respond to the SPRQ-Nx launch and its impact on pricing will be critical in shaping the long-term competitive landscape of the long-read sequencing market.

PacBio Integrates Long-Read Sequencing into Global Rare Disease Network

Event summary

  • PacBio is partnering with iHope, a global rare disease genomics program, to integrate its HiFi long-read sequencing technology.
  • iHope supports over 1,000 patients annually across 14 countries with a network of 25 clinical sites.
  • The collaboration aims to expand genomic insights for rare disease diagnosis and potentially support precision therapeutic approaches.
  • Integration of PacBio’s sequencing is expected to begin in early 2026.

The big picture

This partnership represents a strategic move for PacBio to expand its reach beyond research labs and into clinical diagnostics, a higher-margin segment of the genomics market. iHope’s global network provides PacBio with immediate access to a large patient population and a platform for demonstrating the clinical utility of long-read sequencing. The collaboration also highlights the increasing importance of multi-technology approaches in rare disease diagnosis, as short-read sequencing alone often fails to identify all relevant genetic variants.

What we're watching

Clinical Adoption
The speed and efficiency of HiFi sequencing integration across iHope’s 25 clinical sites will be a key indicator of PacBio’s ability to scale its technology into complex, distributed networks.
Diagnostic Impact
The actual improvement in diagnostic rates for previously undiagnosed rare disease patients, attributable to PacBio’s long-read sequencing, will be crucial to justifying the investment and expanding the partnership.
Therapeutic Pipeline
Whether the collaboration yields tangible progress in identifying targets for antisense oligonucleotide therapies will determine the long-term strategic value of this partnership for PacBio.

PacBio Sells Short-Read Assets to Illumina for $48.1 Million

Event summary

  • PacBio completed the sale of its short-read sequencing assets and related intellectual property to Illumina on January 30, 2026.
  • The company received $48.1 million in net cash proceeds from the transaction.
  • Illumina assumed certain liabilities and granted PacBio a non-exclusive license to certain intellectual property.
  • PacBio cited challenging macroeconomic conditions as the reason for pausing short-read sequencing platform development in 2025.

The big picture

PacBio's decision to sell its short-read assets and focus solely on long-read sequencing reflects a broader trend in the genomics market towards increasingly complex and comprehensive data analysis. The deal allows Illumina to expand its portfolio, while PacBio aims to streamline operations and concentrate resources on its core long-read technology, which is increasingly vital for applications like human germline sequencing and oncology research. This move signals a potential shift in competitive dynamics within the sequencing market, with long-read technologies gaining prominence.

What we're watching

Financial Impact
The $48.1 million windfall provides PacBio immediate liquidity, but the long-term impact on revenue streams previously associated with the short-read technology warrants close monitoring.
SPRQ-Nx Launch
The accelerated development and global launch of PacBio’s SPRQ-Nx chemistry will be a key indicator of the company’s ability to maintain competitive pricing and capture market share in the long-read sequencing space.
Long-Read Adoption
The success of PacBio's strategic pivot hinges on driving adoption of its long-read sequencing platform; the pace of this adoption will determine whether the company can justify its focus and offset the lost revenue from the divested assets.

PacBio Collaboration Targets Rare Disease Therapies with Long-Read Sequencing

Event summary

  • PacBio is collaborating with n-Lorem Foundation and EspeRare to advance antisense oligonucleotide (ASO) therapies for rare genetic diseases.
  • The collaboration will leverage PacBio’s HiFi long-read whole genome sequencing technology to improve ASO design and target validation.
  • PacBio will donate sequencing reagents and provide scientific expertise to support the research.
  • n-Lorem Foundation has approved over 200 nano-rare patients for treatment and is seeking treatment applications from over 380 patients.

The big picture

The collaboration underscores the growing trend toward individualized therapies and the increasing importance of genomic data in drug development. PacBio’s involvement positions it as a critical infrastructure provider in a niche market with potentially high margins, but also significant regulatory and logistical complexities. The partnership also highlights the rise of non-profit organizations like n-Lorem, which are disrupting traditional pharmaceutical development models by focusing on ultra-rare diseases.

What we're watching

Commercial Adoption
The success of this collaboration hinges on whether long-read sequencing becomes a standard practice in ASO development, which will dictate PacBio’s ability to expand its services to other therapeutic areas.
Regulatory Pathway
The reliance on patient-specific regulatory pathways for ASO therapies could create unique hurdles and opportunities for PacBio, requiring close monitoring of evolving regulatory frameworks.
n-Lorem Scale
n-Lorem’s ability to manage the increasing demand for treatments, currently exceeding 200 patients, will be a key factor in determining the long-term value and scalability of the collaboration.

PacBio Revenue Growth Slows Amidst SPRQ-Nx Rollout

Event summary

  • PacBio reported preliminary Q4 2025 revenue of $44.6 million, up 14% year-over-year.
  • Full-year 2025 revenue reached $160.0 million, a 4% increase compared to 2024.
  • Instrument revenue decreased to $17.3 million in Q4 2025, down from $15.3 million in Q4 2024, but decreased annually to $53.8 million from $65.8 million.
  • Consumables revenue saw a significant increase, reaching $21.6 million in Q4 2025 and $81.9 million for the full year.
  • Ending cash, cash equivalents, and investments decreased to $279.5 million from $389.9 million in the prior year.

The big picture

PacBio's slowing revenue growth, despite increased consumables sales, highlights the challenges of transitioning to a new platform (SPRQ-Nx) and maintaining momentum in a competitive long-read sequencing market. The company's focus on clinical applications and cost reduction is a strategic pivot, but the execution risk is significant given the capital intensity of the sequencing market and the need for broad clinical validation. The decrease in cash reserves also warrants attention, as PacBio navigates this transition period.

What we're watching

Execution Risk
The success of the SPRQ-Nx platform will be critical to PacBio’s stated growth plans, and the company’s ability to deliver on cost reductions and clinical adoption will be closely scrutinized.
Instrument Demand
The decline in instrument revenue warrants investigation; whether this is a temporary effect of the SPRQ-Nx transition or a sign of broader market shifts needs to be assessed.
Clinical Adoption
The pace at which real-world evidence translates into increased clinical sequencing applications will determine the sustainability of consumables revenue growth and overall profitability.

PacBio Gains Foothold in SUDC Research with First-Line Sequencing

Event summary

  • PacBio’s HiFi long-read sequencing technology will be used as the initial diagnostic approach for Sudden Unexplained Death in Childhood (SUDC) research.
  • The research effort is led by Danny Miller, MD, PhD, and Alexandra Keefe, MD, PhD, at UW Medicine and Seattle Children’s, and backed by the SUDC Foundation.
  • The University of Washington team will join the HiFi Solves Global Consortium to study the broader clinical applications of HiFi sequencing.
  • The initiative aims to improve diagnostic yield by resolving complex genetic variants, including structural variants and tandem repeats, by incorporating parental data.

The big picture

This collaboration represents a strategic win for PacBio, positioning its HiFi technology in a high-value, emotionally charged area of clinical diagnostics. The SUDC Foundation’s backing and the University of Washington’s involvement lend significant credibility to the technology’s potential. While the SUDC market itself is relatively small, successful application here could serve as a proof-of-concept for broader adoption in rare disease diagnostics, a market with significant unmet need and potential for growth.

What we're watching

Clinical Adoption
The success of HiFi sequencing in SUDC research could accelerate its adoption in other rare disease diagnostics, potentially expanding PacBio’s addressable market beyond research applications.
Regulatory Pathway
The use of HiFi sequencing in clinical diagnostics will likely face regulatory scrutiny, and the speed of approval will impact PacBio’s ability to commercialize the technology in this area.
Competitive Landscape
Other sequencing technologies may challenge HiFi’s position as the first-line assay, and PacBio’s ability to maintain a cost and performance advantage will be critical for sustained adoption.

PacBio's CiFi Method Dramatically Improves Genome Assembly Speed and Accuracy

Event summary

  • PacBio and UC Davis researchers jointly developed CiFi, a new method for long-read 3C genome sequencing.
  • CiFi integrates chromatin conformation capture (3C) with PacBio HiFi sequencing to generate chromosome-scale, haplotype-resolved genome assemblies from a single sequencing run.
  • The method's capabilities were demonstrated with prairie and meadow vole genome assemblies, achieving scaffold N50 values exceeding 100 million base pairs.
  • CiFi utilizes PacBio's Revio SPRQ chemistry to reduce the number of cells, libraries, and sequencing runs required for reference-quality genome assemblies.

The big picture

CiFi represents a significant advancement in genome sequencing, addressing limitations of existing Hi-C methods and lowering the barrier to entry for complex genomic projects. This innovation strengthens PacBio's position in the rapidly growing long-read sequencing market, which is crucial for advancements in personalized medicine, agricultural biotechnology, and fundamental biological research. The ability to generate high-quality assemblies with fewer resources could unlock new research avenues and accelerate scientific discovery.

What we're watching

Adoption Rate
The speed at which CiFi is adopted by research institutions and commercial entities will determine its impact on PacBio's revenue and market share in the long-read sequencing space.
Competitive Response
Competitors in the long-read sequencing market will likely evaluate CiFi and may develop competing technologies or approaches to address its advantages.
Expansion Scope
How PacBio expands the application of CiFi beyond genome biology, biodiversity studies, and functional genomics will reveal the full extent of its strategic value.

PacBio to Present at J.P. Morgan Healthcare Conference

Event summary

  • PacBio (PACB) will present at the 44th Annual J.P. Morgan Healthcare Conference.
  • The presentation is scheduled for January 12, 2026, at 10:30 AM PT.
  • A live webcast will be available on PacBio’s investor relations page.
  • The webcast replay will be accessible for at least 30 days following the event.

The big picture

PacBio's presence at J.P. Morgan Healthcare Conference signals an effort to engage with key investors and analysts. The conference provides a platform to articulate the company's strategy and address concerns around the adoption rate of long-read sequencing, a technology increasingly vital for complex genomic research. The company's ability to effectively communicate its value proposition will be crucial for maintaining investor confidence in a sector facing increasing competition and regulatory scrutiny.

What we're watching

Investor Sentiment
The conference presentation will be a key indicator of investor sentiment towards PacBio's long-term growth prospects, particularly given the competitive landscape in genomic sequencing.
Commercial Adoption
The pace at which PacBio can demonstrate increased adoption of its HiFi sequencing technology across diverse research applications will be critical to sustaining its valuation.
Competitive Pressure
How PacBio addresses the ongoing competitive pressure from alternative sequencing technologies and larger players in the genomics space will influence its market share and profitability.
CID: 470